Page 67 - IMO-1-1

Innovative Medicines & Omics Antioxidant nanomedicines for therapies

clearance, and long-term fate of clinically relevant Classification of chronic hepatitis: Diagnosis, grading and
nanomaterials. Adv Mater. 2018;30(19):e1704307. staging. Hepatology. 1994;19(6):1513-1520.
doi: 10.1002/adma.201704307 doi: 10.1002/hep.1840190629
317. Williams R. Global challenges in liver disease. Hepatology. 329. Al Mamun A, Wu Y, Jia C, et al. Role of pyroptosis in liver
2006;44(3):521-526. diseases. Int Immunopharmacol. 2020;84:106489.
doi: 10.1002/hep.21347 doi: 10.1016/j.intimp.2020.106489
318. Montalvo-Jave EE, Pina E, Montalvo-Arenas C, et al. Role 330. Hurtado-Navarro L, Angosto-Bazarra D, Pelegrin P, Baroja-
of ischemic preconditioning in liver surgery and hepatic Mazo A, Cuevas S. NLRP3 inflammasome and pyroptosis
transplantation. J Gastrointest Surg. 2009;13(11):2074-2083. in liver pathophysiology: The emerging relevance of Nrf2
inducers. Antioxidants (Basel). 2022;11(5):870.
doi: 10.1007/s11605-009-0878-7
doi: 10.3390/antiox11050870
319. Jaeschke H. Reactive oxygen and ischemia/reperfusion
injury of the liver. Chem Biol Interact. 1991;79(2):115-136. 331. Devant P, Borsic E, Ngwa EM, et al. Gasdermin
D pore-forming activity is redox-sensitive. Cell
doi: 10.1016/0009-2797(91)90077-k
Rep. 2023;42(1):112008.
320. Fondevila C, Busuttil RW, Kupiec-Weglinski JW. Hepatic doi: 10.1016/j.celrep.2023.112008
ischemia/reperfusion injury--a fresh look. Exp Mol Pathol.
2003;74(2):86-93. 332. Zhang J, Gao B, Ye B, et al. Mitochondrial-targeted
delivery of polyphenol-mediated antioxidases complexes
doi: 10.1016/s0014-4800(03)00008-x
against pyroptosis and inflammatory diseases. Adv Mater.
321. Wang H, Xi Z, Deng L, Pan Y, He K, Xia Q. Macrophage 2023;35(11):e2208571.
polarization and liver ischemia-reperfusion injury. Int J
Med Sci. 2021;18(5):1104-1113. doi: 10.1002/adma.202208571
333. Gines P, Krag A, Abraldes JG, Sola E, Fabrellas N, Kamath
doi: 10.7150/ijms.52691
PS. Liver cirrhosis. Lancet. 2021;398(10308):1359-1376.
322. Kim JY, Lee DY, Kang S, et al. Bilirubin nanoparticle doi: 10.1016/S0140-6736(21)01374-X
preconditioning protects against hepatic ischemia-
reperfusion injury. Biomaterials. 2017;133:1-10. 334. Torok NJ. Dysregulation of redox pathways in liver
fibrosis. Am J Physiol Gastrointest Liver Physiol.
doi: 10.1016/j.biomaterials.2017.04.011
2016;311(4):G667-G674.
323. Jung E, Song N, Lee Y, Kwon G, Kwon S, Lee D. H(2) doi: 10.1152/ajpgi.00050.2016
O(2)-activatable hybrid prodrug nanoassemblies as a
pure nanodrug for hepatic ischemia/reperfusion injury. 335. Wang S, Friedman SL. Hepatic fibrosis: A convergent
Biomaterials. 2022;284:121515. response to liver injury that is reversible. J Hepatol.
2020;73(1):210-211.
doi: 10.1016/j.biomaterials.2022.121515
doi: 10.1016/j.jhep.2020.03.011
324. Manne N, Arvapalli R, Graffeo VA, et al. Prophylactic
treatment with cerium oxide nanoparticles attenuate 336. Zhou WC, Zhang QB, Qiao L. Pathogenesis of liver
hepatic ischemia reperfusion injury in Sprague Dawley cirrhosis. World J Gastroenterol. 2014;20(23):7312-7324.
rats. Cell Physiol Biochem. 2017;42(5):1837-1846. doi: 10.3748/wjg.v20.i23.7312
doi: 10.1159/000479540 337. Zhang DQ, Sun P, Jin Q, et al. Resveratrol regulates
325. Ni D, Wei H, Chen W, et al. Ceria nanoparticles meet activated hepatic stellate cells by modulating NF-kappaB
hepatic ischemia-reperfusion injury: The perfect and the PI3K/Akt signaling pathway. J Food Sci.
imperfection. Adv Mater. 2019;31(40):e1902956. 2016;81(1):H240-H245.
doi: 10.1002/adma.201902956 doi: 10.1111/1750-3841.13157
326. Hoofnagle JH, di Bisceglie AM. The treatment of chronic 338. Singh AP, Singh R, Verma SS, et al. Health benefits of
viral hepatitis. N Engl J Med. 1997;336(5):347-356. resveratrol: Evidence from clinical studies. Med Res Rev.
2019;39(5):1851-1891.
doi: 10.1056/NEJM199701303360507
doi: 10.1002/med.21565
327. Gao B, Bataller R. Alcoholic liver disease: Pathogenesis and new
therapeutic targets. Gastroenterology. 2011;141(5):1572-1585. 339. Wang Y, Liu Y, Liu Y, et al. Remodeling liver
microenvironment by L-arginine loaded hollow
doi: 10.1053/j.gastro.2011.09.002
polydopamine nanoparticles for liver cirrhosis treatment.
328. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Biomaterials. 2023;295:122028.

Volume 1 Issue 1 (2024) 61 doi: 10.36922/imo.2527